Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Bioasis Technologies Inc. V.BTI

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to... see more

TSXV:BTI - Post Discussion

Bioasis Technologies Inc. > recent press and videos
View:
Post by chrispi on Jul 09, 2021 12:57pm

recent press and videos

Two new videos about Bioasis were released this week from https://equity.guru/ :
 
1.     Jody Vance interview with Deborah Rathjen (Executive Chair, Bioasis)
https://www.youtube.com/watch?v=w7Lmh3hc9Pw
 
2.     2 min 56 sec Company Overview
https://www.youtube.com/watch?v=w1XXYEr9a4s
 
In addition to the three recent articles from them:
https://equity.guru/2021/07/07/bioasis-technologies-bti-v-announces-positive-results-from-xb3-il-1ra-study/
 
https://equity.guru/2021/07/06/bioasis-technologies-bti-v-stock-is-on-the-move-following-scientific-validation-of-xb3-platform/
 
https://equity.guru/2021/07/02/bioasis-bti-v-begins-research-collaboration-oxyrane-uk-appoints-new-cfo/
 
and their original introduction article https://equity.guru/2021/06/03/bioasis-technologies-bti-v-biopharma-dark-horse-in-the-making/
 
And this article https://themarketherald.ca/bioasis-announces-positive-results-from-an-efficacy-study-of-xb3tm-il-1ra-in-a-model-of-multiple-sclerosis-2021-07-07/ , although not giving additional scientific data, does an excellent job of summarizing the il-1ra study press release in an easy-to-understand way for non-biotech people.
Comment by Finallytherock on Jul 09, 2021 1:20pm
Much appreciate that you provided this post showing the recent news releases. I think it helps that they get the word out on multiple outlets. Clearly, judging by the volume, very few people know about this company. I was disappointed the recent news didn't get us moving. I know the data is still very early and they did not provide much detail but still. We need to hear from Chiasi and ...more  
Comment by prophetoffacts on Jul 09, 2021 5:02pm
This post has been removed in accordance with Community Policy
Comment by beenthere on Jul 12, 2021 8:31am
A great reply to this post and a follow up from Aarcor  by Narmac over on Agora. I would suggest he post it here as well.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities